Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women

Fertility and Sterility

Volumn 70, Issue 6, 1998, Pages 1085-1089

  Mijatovic, Velja ^a   Netelenbos, Coen ^a   Van Der Mooren, Marius J ^a   De Valk De Roo, Gerdien W ^a   Jakobs, Cornelis ^a   Kenemans, Peter ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Estrogen; Homocysteine; Hormone replacement therapy; Postmenopausal; Raloxifene

Indexed keywords

CALCIUM CARBONATE; CONJUGATED ESTROGEN; ESTRADIOL; FOLLITROPIN; HOMOCYSTEINE; PLACEBO; RALOXIFENE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART PROTECTION; HUMAN; HUMAN EXPERIMENT; HYSTERECTOMY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION;

ADMINISTRATION, ORAL; ANIMALS; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FASTING; FEMALE; HOMOCYSTEINE; HORSES; HUMANS; HYSTERECTOMY; MIDDLE AGED; PIPERIDINES; PLACEBOS; POSTMENOPAUSE; RALOXIFENE; RECEPTORS, ESTROGEN; REFERENCE VALUES;

EID: 0032403666     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(98)00381-1     Document Type: Article

References (25)

1. Boushey C.J., Beresford S.A.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 274:1995;1049-1057.
2. Stampfer M.J., Malinow M.R., Willett W.C., Newcomer L.M., Upson B., Ullman D., et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 268:1992;877-881.
3. Nygård O., Nordrehaug E.J., Refsum H., Ueland P.M., Farstad M., Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 337:1997;230-236.
4. Wouters M.G.A.J., Moorrees M.T.H.E.C., van der Mooren M.J., Blom H.J., Boers G.H.J., Schellekens L.A., et al. Plasma homocysteine and menopausal status. Eur J Clin Invest. 25:1995;801-805.
5. Grodstein F., Stampfer M.J., Manson J.E., Colditz G.A., Willett W.C., Rosner B., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 335:1996;453-461.
6. Pines A., Mijatovic V., van der Mooren M.J., Kenemans P. Hormone replacement therapy and cardioprotection basic concepts and clinical considerations . Eur J Obstet Gynecol Reprod Biol. 71:1997;193-197.
7. Van der Mooren M.J., Wouters M.G.A.J., Blom H.J., Schellekens L.A., Eskes T.K.A.B., Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest. 24:1994;733-736.
8. Breast cancer and hormone replacement therapy collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer . Lancet. 350:1997;1047-1059.
9. Kauffman R., Bryant H. Selective estrogen receptor modulators. Drug News & Perspectives. 8:1995;531-539.
10. Yang N.N., Venugopalan M., Hardikar S., Glasebrook A. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science. 273:1996;1222-1225.
11. Black L.J., Sato M., Rowley E.R., Magee D.E., Bekele A., Williams D.C., et al. Raloxifene (LY 139481) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 93:1995;63-69.
12. Draper M.W., Flowers D.E., Huster W.J., Neild J.A., Harper K.D., Arnaud C. A controlled trial of raloxifene (LY 139481) HCL impact on bone turnover and serum lipid profile in healthy postmenopausal women . J Bone Miner Res. 11:1996;835-842.
13. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A., Shah A.S., Huster W.J., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 337:1997;1641-1647.
14. McDonald C.C., Alexander F.E., Thyte B.W., Forrest A.P., Stewart H.J. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. Br Med J. 311:1995;977-980.
15. McDonald C.C., Stewart H.J. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br Med J. 303:1991;435-437.
16. Ubbink J.B., Vermaak W.H.J., Bissbort S. Rapid high performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr. 565:1991;441-446.
17. Mijatovic V., Kenemans P., Jakobs C., Van Baal W.M., Peters-Muller E.R.A., Van der Mooren M.J. A randomized controlled study of the effects of 17 beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women. Obstet Gynecol. 91:1998;432-436.
18. Mijatovic V., Kenemans P., Netelenbos J.C., Jakobs C., Popp-Snijders C., Peters-Muller E.R.A., et al. Postmenopausal oral 17β-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil Steril. 69:1998;876-882.
19. Anker G., Lønning P.E., Ueland P.M., Refsum H., Lien E.A. Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen. Int J Cancer. 60:1995;365-368.
20. Rees M.M., Rodgers G.M. Homocysteinemia association of a metabolic disorder with vascular disease and thrombosis . Thromb Res. 71:1993;337-359.
21. Harpel P.C., Zhang X., Borth W. Homocysteine and hemostasis pathogenic mechanisms predisposing to thrombosis . J Nutr. 126:(4 Suppl):1996;1285S-1289S.
22. Tawakol A., Omland T., Gerhard M., Wu J.T., Creager M.A. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 95:1997;1119-1121.
23. Kim M.H., Kim E., Passen E.L., Meyer J., Kang S.S. Cortisol and estradiol non-genetic factors for hyperhomocyst(e)inemia . Metabolism. 46:1997;247-249.
24. Finkelstein J. Methionine metabolism in mammals. Effect of age, diet, and hormones on three enzymes of the pathway in rat tissues. Arch Biochem Biophys. 122:1972;583-590.
25. Blom H.J., Boers G.H.J., Elzen J.P.A.M., Van Roessel J.J.M., Trijbels J.M.F., Tangerman A. Difference between premenopausal women and young men in the transamination pathway of methionine catabolism and the protection against vascular disease. Eur J Clin Invest. 18:1988;633-638.